AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
LSE:AZN
Price:
11 988 GBX
-0.32%
Market Closed
Updated:
Apr 28, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
140.5
Current
153.2
Median
13.6
Industry
Lower
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=140.5
Enterprise Value
/
1.6T
EBITDA
14.3B
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
185.8B GBP | 140.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
696.4B USD | 60.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 34.6 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 1 771.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
351.8B USD | 11.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.2B USD | 45.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.9B CHF | 9.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
176.2B CHF | 8.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
143.4B USD | 10.3 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
1.1
2-Years Forward
EV/EBITDA
1
3-Years Forward
EV/EBITDA
0.9
You don't have any saved screeners yet
